# Daniel O'Connell

Type: Person

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/daniel-oconnell
Canonical HTML page: https://gethealthbrief.com/entity/daniel-oconnell

## Timeline

- **2026-Q4**: Strategic Review — Evaluation of Phase II results to determine Phase III trial design and regulatory pathways.
- **2026**: Catalyst Year Launch — Anticipated period for major clinical updates and potential Phase II data readouts.
- **2025**: EBD Research Progress — Ongoing development of the enhanced brain delivery version of sabirnetug with JCR Pharmaceuticals.
- **2024-Q3**: Phase II Dosing — Acumen continues enrollment and dosing for the sabirnetug Phase II clinical program.

## Recent coverage (1 stories)

### Acumen Pharmaceuticals Signals 2026 Breakthrough for Alzheimer’s Pipeline
2026-03-19 12:22:30 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Acumen Pharmaceuticals (NASDAQ: ABOS) has identified 2026 as a pivotal catalyst year as it advances its lead Alzheimer’s candidate, sabirnetug, through Phase II trials. The company is simultaneously leveraging a strategic partnership with JCR Pharmaceuticals to implement enhanced brain delivery (EBD) technology, aiming to overcome the blood-brain barrier challenges that have historically hindered neurodegenerative treatments.
Full story: https://gethealthbrief.com/story/acumen-pharmaceuticals-sabirnetug-alzheimers-2026-catalyst

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.